

## Wakix - (4.45 and 17.8 mg; Tablet)

|                              |   |                             |                         |
|------------------------------|---|-----------------------------|-------------------------|
| <b>Generic Name</b>          | Pitolisant Hydrochloride  | <b>Innovator</b>            | Harmony Biosciences LLC |
| <b>Dosage</b>                | 4.45 and 17.8 mg; Tablet  | <b>Branded US Sales</b>     | Less Than \$1000 mn     |
| <b>Probable FTF</b>          | More Than 5   | <b>Known Para IV Filers</b> | More Than 5             |
| <b>Other ANDA developers</b> | Less Than 5   | <b>Tentative Approvals</b>  | Less Than 5             |
| <b>Final Approvals</b>       | None  | <b>Generic Launches</b>     | None                    |
| <b>Indication</b>            | Wakix is a histamine-3 (H3) receptor antagonist/inverse agonist indicated for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. |                             |                         |
| <b>Complexities</b>          | Yes   |                             |                         |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.